Document Detail

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
MedLine Citation:
PMID:  21959045     Owner:  NLM     Status:  MEDLINE    
The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients. We conducted a phrase III trial in which patients with previously untreated mCRC were randomized 2:1 to the mIFL [irinotecan (125 mg/m(2)), leucovorin (20 mg/m(2)) bolus, and 5-fluorouracil intravenous infusion (500 mg/m(2)) weekly for four weeks every six weeks] plus bevacizumab (5 mg/kg every two weeks) group and the mIFL group, respectively. Co-primary objectives were progression-free survival (PFS) and 6-month PFS rate. In total, 214 patients were enrolled. Our results showed that addition of bevacizumab to mIFL significantly improved median PFS (4.2 months in the mIFL group vs. 8.3 months in the bevacizumab plus mIFL group, P < 0.001), 6-month PFS rate (25.0% vs. 62.6%, P < 0.001), median overall survival (13.4 months vs. 18.7 months, P = 0.014), and response rate (17% vs. 35%, P = 0.013). Grades 3 and 4 adverse events included diarrhea (21% in the mIFL group and 26% in the bevacizumab plus mIFL group) and neutropenia (19% in the mIFL group and 33% in the bevacizumab plus mIFL group). No wound-healing complications or congestive heart failure occurred. Our results suggested that bevacizumab plus mIFL is effective and well tolerated as first-line treatment for Chinese patients with mCRC. Clinical benefit and safety profiles were consistent with those observed in pivotal phase III trials with mainly Caucasian patients.
Zhong-Zhen Guan; Jian-Ming Xu; Rong-Cheng Luo; Feng-Yi Feng; Li-Wei Wang; Lin Shen; Shi-Ying Yu; Yi Ba; Jun Liang; Dong Wang; Shu-Kui Qin; Jie-Jun Wang; Jing He; Chuan Qi; Rui-Hua Xu
Related Documents :
2240375 - Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echi...
12501895 - Effectiveness of ranitidine bismuth citrate based triple therapy for treating helicobac...
21950285 - Treatment of acne scarring.
22114405 - Comparative investigation of clinical/radiographical signs of mineral trioxide aggregat...
6180675 - Treatment of lymphoid neoplasias with interferon. i. human fibroblastic beta-interferon...
19955955 - Experience and efficacy of a bipolar vessel sealing system for radical abdominal hyster...
Publication Detail:
Type:  Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Chinese journal of cancer     Volume:  30     ISSN:  1000-467X     ISO Abbreviation:  Chin J Cancer     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-30     Completed Date:  2013-01-31     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  101498232     Medline TA:  Chin J Cancer     Country:  China    
Other Details:
Languages:  eng     Pagination:  682-9     Citation Subset:  IM    
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / adverse effects,  therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Asian Continental Ancestry Group
Camptothecin / administration & dosage,  adverse effects,  analogs & derivatives
Colorectal Neoplasms / drug therapy*,  pathology
Diarrhea / chemically induced
Disease-Free Survival
Fluorouracil / administration & dosage,  adverse effects
Leucovorin / administration & dosage,  adverse effects
Middle Aged
Neoplasm Metastasis
Neutropenia / chemically induced
Prospective Studies
Survival Rate
Young Adult
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab; 51-21-8/Fluorouracil; 58-05-9/Leucovorin; 7673326042/irinotecan; 7689-03-4/Camptothecin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular genetics of ependymoma.
Next Document:  Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells.